Zhijun Tang | Molecular Biology | Best Researcher Award

Assoc. Prof. Dr. Zhijun Tang | Molecular Biology | Best Researcher Award

Researcher at Shanghai Institute of Organic Chemistry, China.

Dr. Zhi-Jun Tang is an accomplished researcher at the Shanghai Institute of Organic Chemistry (SIOC) under the Chinese Academy of Sciences. With a focus on chemical biology, Dr. Tang has made significant contributions to the fields of natural product biosynthesis, synthetic biology, biocatalysis, and protein engineering. His work has led to numerous publications in prestigious journals and presentations at national and international conferences. Dr. Tang’s research is characterized by a strong emphasis on understanding the enzymatic processes involved in the biosynthesis of natural products, contributing to the development of new biocatalytic methods and expanding the potential applications of these natural compounds in various industries. As he continues to advance his research, Dr. Tang remains committed to mentoring young scientists and fostering collaborations to enhance scientific discovery.

Education

Dr. Zhi-Jun Tang obtained his Bachelor of Science degree in Chemistry from Sichuan University in July 2014. He then pursued his Ph.D. in Chemical Biology at the Shanghai Institute of Organic Chemistry (SIOC), Chinese Academy of Sciences, under the supervision of Prof. Wen Liu, graduating in July 2019. During his doctoral studies, he engaged in groundbreaking research involving the biosynthesis of natural products and the mechanisms underlying enzymatic reactions. His academic background, combined with rigorous research training, has equipped Dr. Tang with a robust foundation in chemical biology and a strong analytical skill set that supports his ongoing research endeavors in the field.

Professional Experience

Dr. Zhi-Jun Tang’s professional trajectory includes significant roles at the Shanghai Institute of Organic Chemistry (SIOC). He has served as an Associate Professor since September 2023, following a tenure as an Assistant Professor from November 2022 to August 2023. Prior to this, he worked as a Research Associate (Postdoc) under Prof. Wen Liu from July 2019 to October 2022, where he conducted pioneering research on natural product-related enzymology, biocatalysis, and fungal resistance mechanisms. His extensive experience in various research projects has enhanced his expertise in natural product synthesis and enzyme engineering. Dr. Tang has also contributed as a Graduate Research Fellow during his doctoral studies, solidifying his reputation as a skilled researcher in the academic community.

Research Interests

Dr. Zhi-Jun Tang’s research interests lie at the intersection of chemical biology and synthetic biology. He specializes in natural products biosynthesis, with a keen focus on elucidating the enzymatic mechanisms that govern the biosynthesis of bioactive compounds. His work also encompasses biocatalysis, where he explores the potential of enzymes in synthetic applications, including cycloaddition reactions and enzymatic fluorination. Furthermore, Dr. Tang investigates protein engineering, aiming to enhance enzyme efficiency and selectivity for various synthetic processes. His research not only contributes to fundamental scientific knowledge but also has practical implications for drug discovery and environmental sustainability through the development of innovative biocatalytic systems.

Research Skills

Dr. Zhi-Jun Tang possesses a diverse range of research skills essential for his work in chemical biology and enzymology. He is proficient in various experimental techniques, including enzymatic assays, molecular cloning, and biochemical characterization of natural products. Dr. Tang has extensive experience with genome mining and bioinformatics tools to identify novel biosynthetic pathways and enzyme functions. Additionally, he employs synthetic biology approaches to engineer enzymes for specific catalytic activities. His ability to integrate theoretical knowledge with practical experimentation allows him to address complex scientific questions effectively. Furthermore, Dr. Tang’s collaborative spirit and communication skills facilitate productive interactions with interdisciplinary teams, enhancing the impact of his research.

Awards and Honors

Dr. Zhi-Jun Tang has received several accolades that reflect his commitment to excellence in research. In 2023, he was appointed as a Youth Editorial Board Member of Innovation Discovery, recognizing his contributions to the scientific community. He was also awarded the prestigious College Graduate Excellence Award of Shanghai in 2019, a testament to his outstanding academic achievements during his studies. In addition, he received the Merit Student distinction from the University of Chinese Academy of Sciences in 2018, highlighting his exceptional performance as a graduate student. These awards underscore Dr. Tang’s dedication to advancing knowledge in his field and his potential for future contributions to chemical biology and related disciplines.

Conclusion

Dr. Zhi-Jun Tang exemplifies the qualities of an outstanding researcher deserving of the Best Researcher Award. His extensive knowledge in chemical biology, coupled with his innovative contributions to the fields of natural products and biocatalysis, has significantly advanced current scientific understanding. With opportunities for growth in international collaboration and mentorship, Dr. Tang is well-positioned to further influence the scientific community and drive impactful research in the future. His dedication to advancing the field, combined with his strong publication record and recognition, makes him a deserving candidate for this prestigious award.

Publications Top Notes

  • Biosynthesis of lincosamide antibiotics: reactions associated with degradation and detoxification pathways play a constructive role
    Authors: D. Zhang, Z. Tang, W. Liu
    Year: 2018
    Citations: 30
  • Black soldier fly larvae effectively degrade lincomycin from pharmaceutical industry wastes
    Authors: X. Luo, Q. Yang, Y. Lin, Z. Tang, J.K. Tomberlin, W. Liu, Y. Huang
    Year: 2022
    Citations: 29
  • Computational investigation of the mechanism of Diels–Alderase PyrI4
    Authors: Y. Zou, S. Yang, J.N. Sanders, W. Li, P. Yu, H. Wang, Z. Tang, W. Liu, K.N. Houk
    Year: 2020
    Citations: 21
  • A cyclase that catalyses competing 2+ 2 and 4+ 2 cycloadditions
    Authors: H. Wang, Y. Zou, M. Li, Z. Tang, J. Wang, Z. Tian, N. Strassner, Q. Yang, …
    Year: 2023
    Citations: 19
  • Biosynthesis of a New Fusaoctaxin Virulence Factor in Fusarium graminearum Relies on a Distinct Path To Form a Guanidinoacetyl Starter Unit Priming …
    Authors: Z. Tang, H. Tang, W. Wang, Y. Xue, D. Chen, W. Tang, W. Liu
    Year: 2021
    Citations: 14
  • Caerulomycin and collismycin antibiotics share a trans-acting flavoprotein-dependent assembly line for 2,2’-bipyridine formation
    Authors: B. Pang, R. Liao, Z. Tang, S. Guo, Z. Wu, W. Liu
    Year: 2021
    Citations: 14
  • Enzymatic [4+ 2] cycloadditions in the biosynthesis of spirotetramates and spirotetronates
    Authors: B. Pang, G. Zhong, Z. Tang, W. Liu
    Year: 2016
    Citations: 14
  • Characterization of a carboxyl methyltransferase in Fusarium graminearum provides insights into the biosynthesis of fusarin A
    Authors: Q. Yang, W. Wang, Y. Lin, Y. Lin, Z. Tang, J. Wang, J. Tao, W. Tang, W. Liu
    Year: 2021
    Citations: 9
  • Biocatalytic Fluoroalkylation Using Fluorinated S-Adenosyl-l-methionine Cofactors
    Authors: W. Ding, M. Zhou, H. Li, M. Li, Y. Qiu, Y. Yin, L. Pan, W. Yang, Y. Du, X. Zhang, …
    Year: 2023
    Citations: 5
  • Enzymatic α-Ketothioester Decarbonylation Occurs in the Assembly Line of Barbamide for Skeleton Editing
    Authors: S. Guo, Y. Sang, C. Zheng, X.S. Xue, Z. Tang, W. Liu
    Year: 2023
    Citations: 4

Lian-Wang Guo | Genetics and Molecular Biology| Best Researcher Award

Dr. Lian-Wang Guo | Genetics and Molecular Biology| Best Researcher Award

Professor at University of Virginia, United States

Dr. Lian-Wang Guo is a Professor of Biomedical Sciences at the University of Virginia with over 20 years of experience in vascular biology and biochemistry. His research primarily focuses on the role of epigenetic modulators in vascular diseases, particularly neointima-associated restenosis. He has been continuously funded by the NIH since 2012 and has published 48 peer-reviewed papers in the past six years, while also filing six patent applications. Dr. Guo’s innovative work includes developing biomimetic nanoplatforms for targeted drug delivery, which are currently in advanced trials for treating vascular conditions. His research integrates basic science with clinical applications, notably through collaboration with Dr. Craig Kent. Dr. Guo is recognized for his significant contributions to vascular epigenetics and has created a rigorous and inclusive training environment for young researchers. His work holds promise for advancing therapeutic strategies and improving clinical outcomes for vascular diseases.

Professional Profile

Education

Dr. Lian-Wang Guo’s educational background is rooted in biology and advanced plant physiology, providing a strong foundation for his extensive research career. He earned his Bachelor of Science degree in Biology from Xinjiang University in China in 1989, followed by a Master of Science in Plant Physiology from the prestigious Chinese Academy of Sciences in 1992. He continued his studies there, earning a Ph.D. in Plant Physiology and Biochemistry in 1995. Driven by a passion for genetics and biochemistry, Dr. Guo completed a postdoctoral fellowship at The Hebrew University of Jerusalem in 1998, where he broadened his research expertise in molecular biology. His educational journey reflects a commitment to understanding complex biological processes, which he has successfully applied to his pioneering work in vascular biology and epigenetics. Dr. Guo’s solid academic training has been instrumental in his innovative research contributions and leadership in biomedical sciences.

Professional Experience

Dr. Lian-Wang Guo is a tenured Professor of Biomedical Sciences at the University of Virginia, specializing in vascular biology and epigenetics. With over 20 years of research experience, Dr. Guo has developed an expertise in chromatin modulators and their role in vascular diseases, particularly in neointima-associated restenosis. He has been continuously funded by the NIH since 2012, and his prolific contributions include 48 peer-reviewed publications and multiple patents, reflecting his leadership in vascular epigenetics research. His laboratory employs advanced molecular techniques such as ChIPseq, RNAseq, bioinformatics, and innovative nanoplatforms for targeted drug delivery. Dr. Guo has also successfully fostered clinical collaborations, including the development of therapeutic interventions currently undergoing large animal trials, with preparations for human studies. A dedicated mentor, he has cultivated a rigorous training environment for students and fellows, helping them transition into independent research careers. His research has garnered numerous awards and recognition from prominent scientific organizations.

Research Interests

Lian-Wang Guo’s research interests center around the intersection of vascular biology, epigenetics, and targeted drug delivery. As a professor of Biomedical Sciences, his work focuses on understanding the role of chromatin modulators, such as EZH2, DOT1L, and BRD4, in vascular diseases, particularly neointima-associated restenosis. By uncovering how these epigenetic regulators influence disease-specific gene expression, he aims to develop precise therapeutic strategies that mitigate pathological vascular remodeling while preserving normal cellular functions. Dr. Guo is also deeply involved in translational research, advancing the use of biomimetic nanoplatforms for targeted, localized drug delivery. His lab has developed innovative nanotechnologies to deliver therapeutic agents to disease sites, aiming to enhance efficacy and minimize side effects. A key element of his research is the integration of basic science discoveries with clinical applications, as evidenced by his collaborations on vascular disease treatments currently in advanced stages of preclinical testing.

Lian-Wang Guo, Professor of Biomedical Sciences at the University of Virginia, has earned numerous prestigious awards and honors throughout his distinguished career. In 1996, he received the Award of Excellent Sci/Tech Articles from the Chinese Society of Plant Physiology. He has also been recognized with the University of Wisconsin-Madison Eye Research Institute Rapid Response Initiative Award (2008), the Morgridge Institute for Research Award (2014), and the New Investigator Award from the State of Wisconsin Partnership Program (2014). At The Ohio State University, he earned the Accelerator Award for Translation (2017). His editorial contributions include serving as Lead Guest Editor for Genes and Associate Editor for Frontiers in Cardiovascular Medicine. In 2023, he was elected as a Fellow of the American Heart Association (FAHA), and his outstanding research earned him recognition at the 2023 Research Achievement event at the University of Virginia, marking him as a leading figure in vascular biology and biomedical research.

Dr. Lian-Wang Guo’s extensive research contributions, particularly in vascular biology and epigenetics, position him as a leading scholar in biomedical sciences. His innovative work on chromatin modulators, specifically targeting epigenetic players like BRD4, EZH2, and DOT1L, has brought new insights into the treatment of neointimal-associated vascular diseases. Additionally, his development of nano-based, targeted drug delivery systems has shown promising translational potential, bridging the gap between basic science and clinical applications. With over 20 years of experience, numerous high-impact publications, NIH funding, and significant patents, Dr. Guo’s work is both cutting-edge and impactful. His mentorship of the next generation of scientists, as well as his collaborations with leading clinicians, further enhance his academic profile. While his contributions are already significant, a continued focus on clinical translation could maximize the impact of his research. Overall, Dr. Guo exemplifies the qualities of an outstanding researcher deserving of recognition.

 

Publication top noted
  • Article: Transmembrane protein TMEM97 and epigenetic reader BAHCC1 constitute an axis that supports pro-inflammatory cytokine expression
    Authors: Li, J., Shen, H., Guo, L.-W.
    Year: 2024
    Citations: 0
  • Article: miR579-3p is an inhibitory modulator of neointimal hyperplasia and transcription factors c-MYB and KLF4
    Authors: Xie, X., Shirasu, T., Li, J., Guo, L.-W., Kent, K.C.
    Year: 2023
    Citations: 3
  • Article: Neointima abating and endothelium preserving — An adventitia-localized nanoformulation to inhibit the epigenetic writer DOT1L
    Authors: Shirasu, T., Yodsanit, N., Li, J., Gong, S., Guo, L.-W.
    Year: 2023
    Citations: 1
  • Article: Targeted PERK inhibition with biomimetic nanoclusters confers preventative and interventional benefits to elastase-induced abdominal aortic aneurysms
    Authors: Yodsanit, N., Shirasu, T., Huang, Y., Gong, S., Wang, B.
    Year: 2023
    Citations: 2
  • Article: Gene-repressing epigenetic reader EED unexpectedly enhances cyclinD1 gene activation
    Authors: Zhang, M., Li, J., Wang, Q., Miller, C.L., Guo, L.-W.
    Year: 2023
    Citations: 3
  • Article: Sphingoid Bases Regulate the Sigma-1 Receptor—Sphingosine and N,N’-Dimethylsphingosine Are Endogenous Agonists
    Authors: Li, J., Satyshur, K.A., Guo, L.-W., Ruoho, A.E.
    Year: 2023
    Citations: 3
  • Article: Retinal Photoreceptor Protection in an AMD-Related Mouse Model by Selective Sigma-1 or Sigma-2 Receptor Modulation
    Authors: Mavlyutov, T.A., Li, J., Liu, X., Pattnaik, B., Guo, L.-W.
    Year: 2022
    Citations: 4
  • Erratum: Correction: miR548ai antagonism attenuates exosome-induced endothelial cell dysfunction (Cell Death Discovery, (2021), 7, 1, (318), 10.1038/s41420-021-00720-9)
    Authors: Xie, X., Guo, L.-W., Kent, C.K.
    Year: 2022
    Citations: 0
  • Article: Differential Responses to Sigma-1 or Sigma-2 Receptor Ablation in Adiposity, Fat Oxidation, and Sexual Dimorphism
    Authors: Li, J., Félix-Soriano, E., Wright, K.R., Stanford, K.I., Guo, L.-W.
    Year: 2022
    Citations: 5
  • Article: SREBP1 regulates Lgals3 activation in response to cholesterol loading
    Authors: Li, J., Shen, H., Owens, G.K., Guo, L.-W.
    Year: 2022
    Citations: 9